$139.48▼ 4.64 (3.22%)
Real-time prices · US Markets100% of 21 covering analysts have a positive rating.
low return on equity (-58%).
Quality
2
Health
7.7
Growth
3.8
Valuation
4.7
Sentiment
9.2
Analyst Target
$174.30
▲ +25.0% from current
Price Chart
Latest News
Fundamentals
Trailing P/E
—
price-to-earnings
Forward P/E
-26.6×
next 12 months est.
Market Cap
$29.7B
market capitalization
Div Yield
—
dividend yield
Profit Margin
0.0%
net profit margin
Gross Margin
0.0%
revenue minus COGS
ROE
-58.1%
return on equity
Beta
1.01
vs S&P 500
Price / Book
—
P/B ratio
52-Week Range
$34 — $156
annual min — max
EPS — Estimate vs Actual
Frequently Asked Questions
Is RVMD a good stock to buy right now?
Revolution Medicines, Inc.'s Q·Score is 5.1/10 (Bearish), reflecting its current fundamentals, analyst data, and valuation metrics. 100% of 21 covering analysts have a positive rating. Key area to monitor: low return on equity (-58%). This is an informational data summary only and does not constitute financial advice. Always do your own research before making any investment decision.
What is the analyst price target for RVMD?
The consensus price target for RVMD is $174.30, based on ratings from 20 Wall Street analysts. This is 25.0% above the current price of $139.48. Price targets are forward-looking estimates and not guarantees of future performance.
Is RVMD overvalued or undervalued?
Revolution Medicines, Inc. (RVMD) scores below peers on valuation metrics, trading above typical sector multiples. The consensus analyst price target of $174.30 is 25% above the current price.
When does Revolution Medicines, Inc. report its next earnings?
Revolution Medicines, Inc. is scheduled to report earnings in 3 days, on May 6, 2026.
What is Revolution Medicines, Inc.'s profit margin?
Revolution Medicines, Inc. has a net profit margin of 0.0%, indicating the company is currently operating at a net loss. Its gross margin stands at 0.0%, reflecting a more cost-intensive business model.
How much debt does Revolution Medicines, Inc. have?
Revolution Medicines, Inc. has a debt-to-equity ratio of 0.26×, reflecting a very low debt-to-equity ratio, signalling a conservatively financed balance sheet. Its current ratio is 7.14×, indicating comfortable short-term liquidity.